IMPLANTABLE DEVICES FOR TREATING HIV

1 . An implantable device comprising a biocompatible, biodegradable polymer mixed with TMC278 and with one or more release-enhancing agents selected from the group consisting of poloxamers, polysorbates, and a combination of dimethyl sulfoxide (DMSO) and poly(vinyl pyrrolidone)(PVP).

2 . The device of claim 1 , wherein the device weighs more than 100 mg.

3 . The device of claim 1 , wherein the device weighs more than 500 mg.

4 . The implantable device of claim 1 , shaped as a cylinder.

5 . The implantable device of claim 4 , having a diameter that is in the range of about 0.5 mm to about 4 mm, and a length that is in the range of about 1.0 cm to about 4 cm.

6 . The implantable device of claim 4 , having a diameter that is in the range of about 1.0 mm to about 3.0 mm, and a length that is in the range of about 1.5 cm to about 3.5 cm.

7 . The device of claim 1 , wherein the device contains from about 10% to about 70%, or from about 40% to about 60%, or from about 50% to about 60%, of TMC278.

8 . The device of claim 1 , wherein the biocompatible, biodegradable polymer is selected from copolymers of lactide (which includes lactic acid, d-, l- and meso lactide) and glycolide (including glycolic acid).

9 . The device of claim 8 , wherein the biocompatible, biodegradable polymer is a copolymer of lactide and glycolide in a molar ratio of about 50% to about 65% lactide to about 35% to about 50% glycolide.

10 . The device of claim 1 , wherein the device contains from about 15% to about 25% of biocompatible, biodegradable polymer.

11 . The device of claim 1 , wherein the release-enhancing agent is a poloxamer.

12 . The device of claim 11 , wherein the release-enhancing agent is poloxamer 338.

13 . The device of claim 1 , wherein the device contains from about 1% to about 40%, or from about 10% to about 30%, or of about 15% to about 25%, of said release-enhancing agent.

14 . The device of claim 1 , wherein the device contains from about 10% to about 80%, or from about 10% to about 30%, or from about 15 to about 25%, e.g. about 20%, of said biocompatible, biodegradable polymer.

15 . The device of claim 1 , wherein when present, the amount of DMSO is in the range of about 3% to about 10%.

16 . The device of claim 1 , administered intermittently at a time interval from about 2 weeks to about 3 months, for treating HIV infection.